Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Assets (2016 - 2025)

Neurocrine Biosciences' Assets history spans 16 years, with the latest figure at $4.6 billion for Q4 2025.

  • For Q4 2025, Assets rose 24.55% year-over-year to $4.6 billion; the TTM value through Dec 2025 reached $4.6 billion, up 24.55%, while the annual FY2025 figure was $4.6 billion, 24.55% up from the prior year.
  • Assets reached $4.6 billion in Q4 2025 per NBIX's latest filing, up from $4.3 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $4.6 billion in Q4 2025 to a low of $1.8 billion in Q1 2021.
  • Average Assets over 5 years is $2.9 billion, with a median of $2.7 billion recorded in 2023.
  • Peak YoY movement for Assets: grew 2.52% in 2022, then skyrocketed 47.15% in 2024.
  • A 5-year view of Assets shows it stood at $2.1 billion in 2021, then increased by 14.29% to $2.4 billion in 2022, then surged by 37.27% to $3.3 billion in 2023, then rose by 14.37% to $3.7 billion in 2024, then grew by 24.55% to $4.6 billion in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Assets are $4.6 billion (Q4 2025), $4.3 billion (Q3 2025), and $3.9 billion (Q2 2025).